

**BIONTECH TO PRESENT INTERIM PHASE I/II DATA FOR INVESTIGATIONAL mRNA VACCINE IN MELANOMA PATIENTS AT AACR ANNUAL MEETING 2017**

- First Clinically Applicable, Systemic RNA-based Cancer Vaccine -

**Mainz, Germany, March 7, 2017** - BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that it will present interim data from an ongoing Phase I/II clinical trial of its Lipo-MERIT vaccine in patients with malignant melanoma at the 2017 Annual Meeting of the American Association for Cancer Research (AACR), taking place April 1 – 5 in Washington, DC. This is the first example of a clinically applied systemic mRNA-based cancer immunotherapy.

Permanent Abstract Number: CT034

Poster: “A First-in-Human Phase I/II Clinical Trial Assessing Novel mRNA-lipoplex Nanoparticles for Potent Melanoma Immunotherapy”

Date: Monday, April 3, 2017

Session: PO.CT01 - Phase I Clinical Trials in Progress

Time: 8:00AM – 12:00PM Eastern Daylight Time

Location: Poster Section 33

The Phase I/II dose escalation Lipo-MERIT trial (NCT02410733) in melanoma patients assesses the safety and tolerability as well as the potency of inducing antigen-specific immune responses of the first systemic mRNA vaccine to be developed based on BioNTech’s mRNA nanoparticle immunotherapy platform.

**About BioNTech AG**

BioNTech is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The company combines all building blocks of individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel checkpoint immunomodulators. BioNTech’s approach is validated by five top-tier corporate partnerships with Genentech, Genmab, Eli Lilly and Company, Sanofi and Bayer Animal Health. Founded in 2008, BioNTech’s shareholders include the MIG Fonds, Salvia and the Strüngmann Family Office, with the Strüngmann Family Office as the majority shareholder.

More information about BioNTech is available at [www.biontech.de](http://www.biontech.de).

For meeting requests or further information, please contact:

**General Inquiries:**

BioNTech AG

Regina Jehle

Tel: +49 6131 9084 1273

Email: [Regina.Jehle@biontech.de](mailto:Regina.Jehle@biontech.de)

**US Media & Investors:**

ICR Healthcare

James Heins / Stephanie Carrington

Tel: +1 203 682 8251

Tel: +1 646 277 1282

Email: [James.Heins@icrinc.com](mailto:James.Heins@icrinc.com)

Email: [Stephanie.Carrington@icrinc.com](mailto:Stephanie.Carrington@icrinc.com)

**International Media & Investor Inquiries:**

akampion

Dr. Ludger Wess / Ines-Regina Buth

Tel: +49 40 8816 5964

Tel: +49 30 2363 2768

Email: [info@akampion.com](mailto:info@akampion.com)